Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

R. M. Myers, S. M. Greiner, M. E. Harvey, G. Griesmann, M. J. Kuffel, S. A. Buhrow, Joel M Reid, Mark J Federspiel, M. M. Ames, David M Dingli, K. Schweikart, A. Welch, Angela Dispenzieri, Kah-Whye Peng, Stephen J Russell

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of our clinical protocol "Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma." Dose-response studies in the KAS-6/1 myeloma xenograft model demonstrated a minimum effective dose of 4 × 106 TCID50 (tissue culture infectious dose 50)/kg. Toxicity studies in measles-naive squirrel monkeys and measles-susceptible transgenic mice were negative at intravenous doses up to 108 and 4 × 108 TCID50/kg, respectively. Abundant viral mRNA, maximal on day 8, was detected in cheek swabs of squirrel monkeys, more so after pretreatment with cyclophosphamide. On the basis of these data, the safe starting dose of MV-NIS for our clinical protocol was set at 1-2 × 104 TCID50/kg (106 TCID50 per patient).

Original languageEnglish (US)
Pages (from-to)700-710
Number of pages11
JournalClinical Pharmacology and Therapeutics
Volume82
Issue number6
DOIs
StatePublished - Dec 2007

Fingerprint

Oncolytic Viruses
Measles virus
Cyclophosphamide
Toxicology
Pharmacology
Saimiri
Measles
Clinical Protocols
Cheek
Multiple Myeloma
Heterografts
Transgenic Mice
Messenger RNA

ASJC Scopus subject areas

  • Pharmacology

Cite this

Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide. / Myers, R. M.; Greiner, S. M.; Harvey, M. E.; Griesmann, G.; Kuffel, M. J.; Buhrow, S. A.; Reid, Joel M; Federspiel, Mark J; Ames, M. M.; Dingli, David M; Schweikart, K.; Welch, A.; Dispenzieri, Angela; Peng, Kah-Whye; Russell, Stephen J.

In: Clinical Pharmacology and Therapeutics, Vol. 82, No. 6, 12.2007, p. 700-710.

Research output: Contribution to journalArticle

@article{540859c248af42909f07dbecc160318b,
title = "Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide",
abstract = "MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of our clinical protocol {"}Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma.{"} Dose-response studies in the KAS-6/1 myeloma xenograft model demonstrated a minimum effective dose of 4 × 106 TCID50 (tissue culture infectious dose 50)/kg. Toxicity studies in measles-naive squirrel monkeys and measles-susceptible transgenic mice were negative at intravenous doses up to 108 and 4 × 108 TCID50/kg, respectively. Abundant viral mRNA, maximal on day 8, was detected in cheek swabs of squirrel monkeys, more so after pretreatment with cyclophosphamide. On the basis of these data, the safe starting dose of MV-NIS for our clinical protocol was set at 1-2 × 104 TCID50/kg (106 TCID50 per patient).",
author = "Myers, {R. M.} and Greiner, {S. M.} and Harvey, {M. E.} and G. Griesmann and Kuffel, {M. J.} and Buhrow, {S. A.} and Reid, {Joel M} and Federspiel, {Mark J} and Ames, {M. M.} and Dingli, {David M} and K. Schweikart and A. Welch and Angela Dispenzieri and Kah-Whye Peng and Russell, {Stephen J}",
year = "2007",
month = "12",
doi = "10.1038/sj.clpt.6100409",
language = "English (US)",
volume = "82",
pages = "700--710",
journal = "Clinical Pharmacology and Therapeutics",
issn = "0009-9236",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide

AU - Myers, R. M.

AU - Greiner, S. M.

AU - Harvey, M. E.

AU - Griesmann, G.

AU - Kuffel, M. J.

AU - Buhrow, S. A.

AU - Reid, Joel M

AU - Federspiel, Mark J

AU - Ames, M. M.

AU - Dingli, David M

AU - Schweikart, K.

AU - Welch, A.

AU - Dispenzieri, Angela

AU - Peng, Kah-Whye

AU - Russell, Stephen J

PY - 2007/12

Y1 - 2007/12

N2 - MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of our clinical protocol "Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma." Dose-response studies in the KAS-6/1 myeloma xenograft model demonstrated a minimum effective dose of 4 × 106 TCID50 (tissue culture infectious dose 50)/kg. Toxicity studies in measles-naive squirrel monkeys and measles-susceptible transgenic mice were negative at intravenous doses up to 108 and 4 × 108 TCID50/kg, respectively. Abundant viral mRNA, maximal on day 8, was detected in cheek swabs of squirrel monkeys, more so after pretreatment with cyclophosphamide. On the basis of these data, the safe starting dose of MV-NIS for our clinical protocol was set at 1-2 × 104 TCID50/kg (106 TCID50 per patient).

AB - MV-NIS is an oncolytic measles virus encoding the human thyroidal sodium iodide symporter (NIS). Here, we report the results of preclinical pharmacology and toxicology studies conducted in support of our clinical protocol "Phase I Trial of Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, with or without Cyclophosphamide, in Patients with Recurrent or Refractory Multiple Myeloma." Dose-response studies in the KAS-6/1 myeloma xenograft model demonstrated a minimum effective dose of 4 × 106 TCID50 (tissue culture infectious dose 50)/kg. Toxicity studies in measles-naive squirrel monkeys and measles-susceptible transgenic mice were negative at intravenous doses up to 108 and 4 × 108 TCID50/kg, respectively. Abundant viral mRNA, maximal on day 8, was detected in cheek swabs of squirrel monkeys, more so after pretreatment with cyclophosphamide. On the basis of these data, the safe starting dose of MV-NIS for our clinical protocol was set at 1-2 × 104 TCID50/kg (106 TCID50 per patient).

UR - http://www.scopus.com/inward/record.url?scp=36148993947&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36148993947&partnerID=8YFLogxK

U2 - 10.1038/sj.clpt.6100409

DO - 10.1038/sj.clpt.6100409

M3 - Article

C2 - 17971816

AN - SCOPUS:36148993947

VL - 82

SP - 700

EP - 710

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

SN - 0009-9236

IS - 6

ER -